Boston, MA & Lakewood, CO – Leading medical technology company Terumo Blood and Cell Technologies (Terumo BCT) and 908 Devices Inc. (Nasdaq: MASS), a pioneer in chemical and biochemical analysis devices, have joined forces to revolutionize cell therapy manufacturing. This groundbreaking collaboration aims to introduce on-line analytics and monitoring capabilities to Terumo BCT’s Quantum Flex Cell Expansion System.
The current landscape of cell and gene therapy manufacturing necessitates advanced automation technologies to streamline processes, improve efficiency, and reduce costs. However, maintaining quality control is still heavily dependent on manual tasks performed by expert staff in clean room environments. This collaboration between Terumo BCT and 908 Devices seeks to overcome these challenges by integrating automation and on-line monitoring.
One of the key innovations brought forth by this partnership is the introduction of 908 Devices’ MAVEN, an on-line glucose and lactate analyzer, to Terumo BCT’s Quantum Flex. By incorporating MAVEN into the system, cell and gene therapy developers can monitor critical process parameters in cell cultures without the need for manual sampling or clean room entry. This groundbreaking development minimizes the risk of contamination, saves time for operators, and enhances process understanding.
“We are thrilled to collaborate with Terumo BCT, a leading innovator in cell therapy technologies, to achieve the next level of process integration in biopharma,” said Kevin J. Knopp, CEO and co-founder of 908 Devices. “Our devices are designed to empower scientists by providing valuable insights that accelerate progress and reduce costs.”
Terumo BCT’s Quantum Flex Cell Expansion System is an automated and functionally closed system designed to cater to the specific needs of cell therapy developers throughout their commercialization journey. With an emphasis on process development, clinical manufacturing, and quality control, Quantum Flex optimizes reproducibility, scalability, and contamination risk reduction. It is compatible with various cell types, including suspension cells, adherent cells, viral vectors, and exosomes.
The integration of 908 Devices’ on-line monitoring capabilities with Terumo BCT’s Quantum Flex platform will significantly reduce time-consuming manual steps, lowering manufacturing costs and minimizing associated risks. By prioritizing collaboration with industry experts, Terumo BCT continues to enhance its solution offering to address the unique challenges faced by the cell therapy industry.
About 908 Devices:
908 Devices specializes in revolutionizing chemical and biochemical analysis through its innovative handheld and desktop devices. These devices are designed to address critical challenges in life sciences research, bioprocessing, pharmaceuticals, forensics, and related fields. By leveraging technologies such as mass spectrometry, microfluidic sampling and separations, software automation, and machine learning, 908 Devices provides quick and actionable answers to researchers and industry professionals.
About Terumo Blood and Cell Technologies:
Terumo Blood and Cell Technologies focuses on providing medical technologies that enable the collection and preparation of blood and cells to treat various diseases and conditions. Their customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers, plasma collection facilities, and private medical practices worldwide. With a global presence and a commitment to innovation, Terumo Blood and Cell Technologies is a leading subsidiary of Terumo Corporation, a renowned global leader in medical technology.
Q: What is the purpose of the collaboration between 908 Devices and Terumo Blood and Cell Technologies?
A: The collaboration aims to introduce on-line analytics and monitoring capabilities to Terumo BCT’s Quantum Flex Cell Expansion System, revolutionizing cell therapy manufacturing.
Q: How will this collaboration benefit the cell therapy developers?
A: The integration of 908 Devices’ on-line monitoring capabilities with Terumo BCT’s Quantum Flex platform will reduce manual steps, lower manufacturing costs, and minimize associated risks for cell therapy developers.
Q: What is MAVEN, and how does it improve the cell therapy manufacturing process?
A: MAVEN is an on-line glucose and lactate analyzer developed by 908 Devices. By incorporating MAVEN into the Quantum Flex platform, cell therapy developers can monitor critical process parameters in cell cultures without manual sampling or clean room entry, reducing the risk of contamination and saving operator time.
– [908 Devices](https://www.908devices.com/)
– [Terumo Blood and Cell Technologies](https://www.terumobct.com/)